四价登革热疫苗亚洲效力试验中中和抗体与序列特异性登革热病的相关性
在CYD14试验中,评估CYD-TDV疫苗接种组与安慰剂组中和抗体滴度与序列特异性症状性经病毒学确诊登革热(VCD)的相关性。疫苗组和安慰剂组中,nAb滴度与VCD的相关性在登革热nAb接触位点序列更接近疫苗插入株时更强。疫苗组风险相关性更强提示不符合Prentice标准,但在基线血清阳性9-14岁人群中两组模式更相似,支持nAb滴度作为该人群的近似替代终点。
要点
- 疫苗组和安慰剂组nAb滴度与序列特异性VCD的相关性在序列更接近疫苗时更强(p=0.005和p=0.012)。
- 疫苗组VCD风险在第90 vs 第10百分位nAb间降低6.7倍(完美匹配病毒),安慰剂组降低1.80倍。
- 基线血清阴性参与者中未见序列特异性nAb滴度与VCD的相关性。
核心结论
- 疫苗组序列距离依赖的风险相关性更强提示不符合Prentice标准,nAb标志物可能因抗体来源(感染或疫苗)不同而对登革热风险影响不同。
- 在基线血清阳性9-14岁人群中,疫苗组与安慰剂组相关性模式更相似,支持nAb滴度作为该人群的近似替代终点。
- 基线血清阴性参与者中未见序列特异性nAb滴度与VCD的相关性。
研究设计与样本
- CYD14试验为四价登革热疫苗CYD-TDV在2-14岁儿童中开展的效力试验,本研究整合nAb与序列数据,分别在疫苗组和安慰剂组评估nAb滴度作为序列特异性VCD的相关标志。
主要发现
- 疫苗组和安慰剂组中,nAb滴度与序列特异性VCD的相关性在登革热nAb接触位点序列更接近疫苗时更强(p=0.005和p=0.012)。
- 疫苗组(安慰剂组)VCD风险在完美匹配CYD-TDV病毒的第90 vs 第10百分位nAb间降低6.7倍(1.80倍),在五个氨基酸错配病毒中降低2.1倍(0.78倍)。
- 限制于基线血清阳性9-14岁人群时,疫苗组与安慰剂组的相关性模式变得更相似。
- 基线血清阴性参与者中未见序列特异性nAb滴度与VCD的相关性。
关键数值与推荐
- 疫苗组序列特异性VCD与nAb滴度相关性p=0.005,安慰剂组p=0.012(序列更接近疫苗时相关性更强)。
- 疫苗组VCD风险在完美匹配病毒第90 vs 第10百分位nAb间降低6.7倍,安慰剂组降低1.80倍。
- 疫苗组VCD风险在五个氨基酸错配病毒第90 vs 第10百分位nAb间降低2.1倍,安慰剂组降低0.78倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the CYD14 trial of the CYD-TDV dengue vaccine in 2-14 year-olds, neutralizing antibody (nAb) titers to the vaccine-insert dengue strains correlated inversely with symptomatic, virologically-confirmed dengue (VCD). Also, vaccine efficacy against VCD was higher against dengue prM/E amino acid sequences closer to the vaccine inserts. We integrated the nAb and sequence data types by assessing nAb titers as a correlate of sequence-specific VCD separately in the vaccine arm and in the placebo arm. In both vaccine and placebo recipients the correlation of nAb titer with sequence-specific VCD was stronger for dengue nAb contact site sequences closer to the vaccine (p = 0.005 and p = 0.012, respectively). The risk of VCD in vaccine (placebo) recipients was 6.7- (1.80)-fold lower at the 90th vs 10th percentile of nAb for viruses perfectly matched to CYD-TDV, compared to 2.1- (0.78)-fold lower at the 90th vs 10th percentile for viruses with five amino acid mismatches. The evidence for a stronger sequence-distance dependent correlate of risk for the vaccine arm indicates departure from the Prentice criteria for a valid sequence-distance specific surrogate endpoint and suggests that the nAb marker may affect dengue risk differently depending on whether nAbs arise from infection or also by vaccination. However, when restricting to baseline-seropositive 9-14 year-olds, the correlation pattern became more similar between the vaccine and placebo arms, supporting nAb titers as an approximate surrogate endpoint in this population. No sequence-specific nAb titer correlates of VCD were seen in baseline-seronegative participants. Integrated immune response/pathogen sequence data correlates analyses could help increase knowledge of correlates of risk and surrogate endpoints for other vaccines against genetically diverse pathogens. Trial registration: EU Clinical Trials Register 2014-001708-24; registration date 2014-05-26.
引用
- Qi L, Sun Y, Juraska M, et al. Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia. Vaccine. 2022. PMID: 36068106. doi:10.1016/j.vaccine.2022.08.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。